Cystatin C as a risk factor for outcomes in chronic kidney disease

被引:164
作者
Menon, Vandana
Shlipak, Michael G.
Wang, Xuelei
Coresh, Josef
Greene, Tom
Stevens, Lesley
Kusek, John W.
Beck, Gerald J.
Collins, Allan J.
Levey, Andrew S.
Sarnak, Mark J.
机构
[1] Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA
[2] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[5] NIH, Bethesda, MD 20892 USA
[6] Univ Utah, Salt Lake City, UT USA
[7] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
关键词
D O I
10.7326/0003-4819-147-1-200707030-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: No study has compared cystatin C level, serum creatinine concentration, and estimated glomerular filtration rate (GFR) as risk factors for outcomes in chronic kidney disease (CKD), and none has compared measured GFR with CKD in any population. Objective: To compare cystatin C level with serum creatinine concentration and iothalamate GFR as risk factors for death and kidney failure. Design: Observational study using serum cystatin C assayed from baseline samples of the Modificztion of Diet in Renal Disease Study (1989-1993). Setting: 15 clinical centers in the United States that participated in the Modification of Diet in Renal Disease Study. Participants: 825 trial participants with stage 3 or 4 nondiabetic CKD who had measurements of serum cystatin C. Measurements: All-cause mortality, cardiovascular (CVD) mortality, and kidney failure until December 2000. Results: Mean cystatin C level, creatinine concentration, and GFR were 2.2 mg/L (SD, 0.7), 212.16 mu mol/L (SD, 88.4) (2.4 mg/dL [SD, 1.0]), and 33 mL/min per 1.73 m(2) (SD, 12), respectively. Median follow-up was 10 years. Twenty-five percent of patients (n = 203) died of any cause, 15% (n = 123) died of CVD, and 66% (n = 548) reached kidney failure. In multivariate-adjusted models, 1-SD decreases in 1/creatinine, GFR, and 1/cystatin C were associated with increased risks for all-cause mortality of 1.27 (95% Cl, 1.06 to 1.49), 1.27 (Cl, 1.08 to 1.49), and 1.41 (Cl, 1.18 to 1.67), respectively. For CVD mortality, the increased risks were 1.32 (Cl, 1.05 to 1.64), 1.28 (Cl, 1.04 to 1.59), and 1.64 (Cl, 1.28 to 2.08), respectively. For kidney failure, the increased risks were 2.81 (Cl, 2.48 to 3.18), 2.41 (Cl, 2.15 to 2.70), and 2.36 (Cl, 2.10 to 2.66), respectively. Limitation: The Modification of Diet in Renal Disease Study cohort may not be representative of all patients with nondiabetic CKD because participants were more likely to reach kidney failure than death in follow-up. Conclusion: The association of cystatin C level with all-cause and CVD mortality was as strong as or perhaps stronger than that of iothalamate GFR with these outcomes in stage 3 or 4 CKD.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 43 条
[1]   Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis [J].
Albert, MA ;
Rifai, N ;
Ridker, PM .
VASCULAR MEDICINE, 2001, 6 (03) :145-149
[2]  
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[3]  
Apperloo AJ, 1996, J AM SOC NEPHROL, V7, P567
[4]   Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment [J].
Coll, E ;
Botey, A ;
Alvarez, L ;
Poch, E ;
Quintó, L ;
Saurina, A ;
Vera, M ;
Piera, C ;
Darnell, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) :29-34
[5]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[6]   Serum cystatin C concentration as a marker of renal dysfunction in the elderly [J].
Fliser, D ;
Ritz, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) :79-83
[7]   Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals [J].
Fried, LF ;
Shlipak, MG ;
Crump, C ;
Bleyer, AJ ;
Gottdiener, JS ;
Kronmal, RA ;
Kuller, LH ;
Newman, AB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) :1364-1372
[8]   Determination of serum cystatin C: Biological variation and reference values [J].
Galteau, MM ;
Guyon, M ;
Gueguen, R ;
Siest, G .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (09) :850-857
[9]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[10]  
GREENE T, 1993, J AM SOC NEPHROL, V4, P1221